Myeloma-Developing Regimens Using Genomics (MyDRUG)
Completed
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Mayo Clinic - Arizona, Phoenix, Arizona +15 locations
Conditions: Relapsed Refractory Multiple Myeloma
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Terminated
Phase 1b: To evaluate the side effects and determine the best dose of ACY-1215 in combination with Pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma. Phase 2: To determine the overall response rate of ACY-1215 in combination with Pomolidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Local Institution - 201, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Active Not Recruiting
This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
Completed
This phase II trial studies how well ixazomib citrate, lenalidomide, and dexamethasone work in treating patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Plasmacytoma, POEMS Syndrome
Comparative Effectiveness of Particulate Versus Nonparticulate Steroid Injections for Musculoskeletal Conditions
Terminated
This aims of this study are: 1. To determine if particulate or non-particulate corticosteroid injections are more effective at treating pain from musculoskeletal pathologies of the hip, glenohumeral joint, biceps tendon, or subacromial/subdeltoid bursa at 2 weeks, 3 months, or 6 months. 2. To determine if there is a significantly different side effect profile between particulate and non-particulate corticosteroids when used for hip, glenohumeral joint, biceps tendon, or subacromial/subdeltoid b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Stanford University, Redwood City, California
Conditions: Osteoarthritis, Tendinopathy, Impingement Shoulder
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
Active Not Recruiting
This phase I/II trial studies the side effects and best dose of venetoclax and how well it works in combination with low-intensity chemotherapy in patients with B- or T-cell acute lymphoblastic leukemia that has not responded to treatment or that has come back. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, including vincristine, cyclophosphamide, dexamethasone, rituximab, methotrexate, and cytarabine, work in dif... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
Active Not Recruiting
This is a Phase II study of daratumumab based therapies for older adults with multiple myeloma.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2025
Locations: H. Lee Moffitt Cancer & Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma
Recruiting
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +1 locations
Conditions: Multiple Myeloma
Perioperative Steroid Dosing on the APR in AIS
Recruiting
The objective of this study is to perform a prospective, randomized controlled trial investigating the clinical usage of perioperative dexamethasone usage on APR activation, postoperative morphine usage, postoperative nausea, and hospital length of stay. There will be a control control and a Dexamethasone cohort. Participants will be randomized into one of the two cohorts. Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesi... Read More
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
02/04/2025
Locations: Children Healthcare of Atlanta, Atlanta, Georgia
Conditions: Adolescent Idiopathic Scoliosis (AIS)
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Active Not Recruiting
The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen. The purpose of the safety/access cohort is to provide continued access to TAK-079 to participants previously enrolled to a TAK-079 parent study and to evaluate the long-term safety profile of TAK-079.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Alabama Oncology, Birmingham, Alabama +8 locations
Conditions: Multiple Myeloma
The Efficacy of Liposomal Bupivacaine in Ultrasound Guided Supraclavicular Nerve Blocks for Hand and Wrist Surgery
Active Not Recruiting
Patients undergoing hand, wrist, and elbow surgery may experience pain after surgery. The orthopedic surgeon may provide prescription pain medications after surgery to assist with pain control. However, with concern of the opioid epidemic, many patients would rather minimize the use of narcotic pain prescriptions after having surgery. As an alternative, ultrasound guided regional nerve blocks can assist with postoperative pain control. patients consented to this study will be randomized into th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: St. Luke's University Health Network, Bethlehem, Pennsylvania
Conditions: Hand Surgery, Wrist Surgery, Elbow Surgery, Fracture Fixation, Dupuytren Contracture, Finger Fracture, Wrist Arthropathy, Distal Radius Fracture
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Active Not Recruiting
This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is no... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
02/01/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +214 locations
Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma